Tekla Total Liab from 2010 to 2024

HQH Stock  USD 17.38  0.13  0.75%   
Tekla Healthcare's Total Liabilities is decreasing with very volatile movements from year to year. Total Liabilities is predicted to flatten to about 1.3 M. Total Liabilities is the total amount of all liabilities that Tekla Healthcare Investors has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
1996-03-31
Previous Quarter
1.1 M
Current Value
1.1 M
Quarterly Volatility
6.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 0.0 or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 14.45, Dividend Yield of 0.0246 or PTB Ratio of 0.58. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
  
Check out the analysis of Tekla Healthcare Correlation against competitors.

Latest Tekla Healthcare's Total Liab Growth Pattern

Below is the plot of the Total Liab of Tekla Healthcare Investors over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Tekla Healthcare's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Very volatile
   Total Liab   
       Timeline  

Tekla Total Liab Regression Statistics

Arithmetic Mean6,612,482
Geometric Mean2,900,291
Coefficient Of Variation140.40
Mean Deviation6,586,353
Median1,321,007
Standard Deviation9,283,883
Sample Variance86.2T
Range34.2M
R-Value(0.03)
Mean Square Error92.7T
R-Squared0
Significance0.90
Slope(72,490)
Total Sum of Squares1206.7T

Tekla Total Liab History

20241.3 M
20231.3 M
20221.1 M
20219.7 M
202015.6 M
20191.1 M
2018M

About Tekla Healthcare Financial Statements

Investors use fundamental indicators, such as Tekla Healthcare's Total Liab, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Liabilities1.3 M1.3 M

Currently Active Assets on Macroaxis

When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:
Check out the analysis of Tekla Healthcare Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.145
Dividend Share
1.66
Earnings Share
1.31
Revenue Per Share
0.197
Quarterly Revenue Growth
(0.06)
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.